IP Library › Patent Application 11836078
Patent Application
App. No. 11/836,078

ANTI-OSTEOPONTIN ANTIBODY AND USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/836,078
Abstract

An anti-osteopontin antibody which inhibits the binding of an integrin recognizing RGD sequence to osteopontin or its fragment, and which inhibits the binding of an integrin recognizing SVVYGLR sequence or sequence equivalent thereto to osteopontin or its fragment. This antibody is useful in remedies for autoimmune diseases, remedies for rheumatism and remedies for rheumatoid arthritis. Also, a method of treating autoimmune disease, rheumatism or rheumatoid arthritis is provided. This antibody is useful in diagnostics and a diagnostic method for rheumatism too.

Claims (13)

1 - 35 . (canceled)

36 . A method for treating arthritis comprising administering an effective amount of an anti-osteopontin antibody to a subject in need thereof, wherein the anti-osteopontin antibody inhibits the binding of the thrombin-cleaved N-terminal fragment of osteopontin to:

(a) an integrin recognizing RGD (arginine-glycine-aspartic acid), and

(b) an integrin having SVVYGLR (SEQ ID NO: 24).

37 . The method claim 36 , wherein said antibody inhibits the binding of thrombin-cleaved N-terminal fragment of osteopontin to an α9β1 integrin.

38 . The method claim 36 , wherein said antibody inhibits the binding of thrombin-cleaved N-terminal fragment of osteopontin to an α4 integrin.

39 . The method claim 36 , wherein said antibody inhibits the binding of thrombin-cleaved N-terminal fragment of osteopontin to an α9β1 integrin and an α4 integrin.

40 . The method claim 36 , wherein said antibody is raised against a peptide containing RGDSVVYGLR (a.a. 1-10 of SEQ ID NO: 15) as the antigen.

41 . The method claim 36 , wherein said antibody is raised against a peptide containing RGDSVVYGLRS (SEQ ID NO: 15) as the antigen.

42 . The method claim 36 , wherein said antibody is raised against VDTYDGRGDSVVYGLRS (amino acids 2-18 of SEQ ID NO: 1) as the antigen.

43 . The method claim 36 , wherein said antibody is a monoclonal antibody.

44 . The method claim 36 , wherein said antibody is a humanized antibody.

45 . The method claim 36 , wherein said antibody is a human-type antibody.